Evidence map›Paper›PMID 36910471›Full record

ArticleOpen life sciences2023

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC.

Ling Zhou, Wenchao Zhang, Yi Xiang, Zijun Qian, Jianping Zhou, Lei Ni, Yun Feng, Beili Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open life sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ling ZhouDepartment of Respiratory Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.
Wenchao ZhangDepartment of Allergy, Henan Provincial People's Hospital, Henan University, Zhengzhou 450000, China.
Yi XiangDepartment of Respiratory Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.
Zijun QianDepartment of Respiratory Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.
Jianping ZhouDepartment of Respiratory Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.
Lei NiDepartment of Respiratory Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.
Yun FengDepartment of Respiratory Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.
Beili GaoDepartment of Respiratory Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains the first treatment choice. Angiogenesis inhibitors are effective for lung cancer treatment. This study explored whether chemotherapy combined with angiogenesis inhibitors could achieve better efficacy in NSCLC. The zebrafish A549 xenograft model was used to investigate the combined effect of apatinib and chemotherapeutic agents in NSCLC. Apatinib combined with pemetrexed demonstrated the highest antitumor effect compared with apatinib combined with gemcitabine or paclitaxel

Indexed as

apatinibNSCLCpemetrexedzebrafish model

Identifiers

PMID36910471
PMCPMC9993329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.